Akums Launches Aztreonam-Avibactam to Combat India's Drug-Resistant Infections
Akums Drugs & Pharmaceuticals has launched Aztreonam-Avibactam, an advanced antibiotic therapy aimed at combating severe multidrug-resistant gram-negative bacterial infections in India. This launch addresses the critical issue of antimicrobial resistance (AMR), a growing global health threat exacerbated by high rates of antibiotic misuse in India. The new therapy targets infections that have become resistant to conventional treatments, offering a vital new option for critical care settings.
Key Highlights
- Akums launched Aztreonam-Avibactam to fight drug-resistant infections in India.
- Antimicrobial resistance (AMR) is a major global health challenge, with India facing high rates of superbugs.
- The new antibiotic targets severe infections unresponsive to conventional treatments.
- India's high antibiotic consumption contributes significantly to the AMR crisis.
- Aztreonam-Avibactam is a combination of aztreonam and avibactam, designed to overcome resistance mechanisms.
- This launch provides a crucial new weapon against increasingly difficult-to-treat bacterial infections.
Akums Drugs & Pharmaceuticals Limited, a leading Indian pharmaceutical contract development and manufacturing organization (CDMO), has announced the launch of Aztreonam-Avibactam Injection. This advanced antibiotic therapy is specifically designed to combat multidrug-resistant gram-negative bacterial infections, which are becoming increasingly prevalent and posing a significant threat to public health. The launch comes at a critical time, as India faces one of the highest rates of drug-resistant infections globally.
Antimicrobial resistance (AMR) is a growing global crisis, and India is disproportionately affected. Studies estimate that hundreds of thousands of deaths in India annually are linked to bacterial infections resistant to existing antibiotics, with projections indicating this number could rise significantly if current trends continue. Factors contributing to this crisis in India include the widespread overuse and misuse of antibiotics, lack of prescription controls, and challenges in infection prevention and control. The ease of access to antibiotics without proper prescriptions and the indiscriminate use in agriculture also exacerbate the problem. This has led to the proliferation of 'superbugs'—bacteria that no longer respond to most available antibiotics, making infections harder and more expensive to treat.
Aztreonam-Avibactam is a novel combination therapy that represents a significant advancement in the fight against these resistant pathogens. Aztreonam is a monobactam antibiotic that is effective against gram-negative bacteria and is particularly stable against metallo-beta-lactamases (MBLs), a class of enzymes that can inactivate most beta-lactam antibiotics. However, aztreonam alone can be degraded by other beta-lactamases, such as extended-spectrum beta-lactamases (ESBLs) and AmpC enzymes, which are often co-produced by resistant bacteria. Avibactam, a novel non-beta-lactam beta-lactamase inhibitor, works by neutralizing these other problematic enzymes. By combining aztreonam with avibactam, the therapy effectively restores aztreonam's activity against a wide spectrum of multidrug-resistant gram-negative bacteria, including those producing MBLs and other difficult-to-treat enzymes.
The launch of Aztreonam-Avibactam by Akums is particularly relevant for India, where infections caused by gram-negative pathogens like *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* are increasingly resistant to existing treatments. These resistant infections are often associated with severe conditions such as hospital-acquired pneumonia, complicated intra-abdominal infections, and severe urinary tract infections, which are common in intensive care settings. The availability of this new combination therapy offers a crucial new option for clinicians managing these life-threatening infections where conventional treatments have failed.
Akums Drugs & Pharmaceuticals Ltd. is India's largest contract development and manufacturing organization (CDMO) with a significant role in the country's pharmaceutical sector. The company has a strong track record of manufacturing and launching various pharmaceutical products. The introduction of Aztreonam-Avibactam by Akums underscores its commitment to addressing critical healthcare needs within India and contributing to the global effort to combat antimicrobial resistance. The therapy has received regulatory approvals in various regions and has demonstrated efficacy in clinical trials for complicated intra-abdominal infections and other serious gram-negative bacterial infections.
Frequently Asked Questions
What is Aztreonam-Avibactam?
Aztreonam-Avibactam is a combination antibiotic therapy. It combines aztreonam, a monobactam antibiotic, with avibactam, a beta-lactamase inhibitor. This combination is designed to effectively combat multidrug-resistant gram-negative bacterial infections.
Why is this antibiotic important for India?
India faces a severe crisis of antimicrobial resistance (AMR), with high rates of drug-resistant infections and significant antibiotic misuse. Aztreonam-Avibactam offers a crucial new treatment option for infections that have become resistant to conventional antibiotics, which are a growing problem in India.
How does Aztreonam-Avibactam work?
Aztreonam is effective against gram-negative bacteria and is resistant to certain enzymes that cause resistance. Avibactam inhibits other enzymes that degrade aztreonam, thereby restoring the antibiotic's effectiveness against a broad spectrum of highly resistant gram-negative bacteria.